BPN14770 (Zatolmilast) 5 mg – 60 tablets
research-grade
tablets
in a sealed bottle. Zatolmilast (BPN-14770) is a selective, allosteric PDE4D inhibitor investigated in laboratory models of cAMP signaling, synaptogenesis, neuroplasticity and cognition.
Research Use Only:
All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Content
5 mg Zatolmilast per tablet
Total tablets
60 tablets (total 300 mg per bottle)
Packaging
Sealed tablet bottle
Storage
Store in a cool, dry place at room temperature; protect from light.
Molecular formula
C21H15ClF3NO2
Molecular weight
≈ 405.8 g·mol⁻¹
IUPAC name
2-[4-[[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl]phenyl]acetic acid
Research Overview
Zatolmilast is employed as a tool compound to interrogate PDE4D-regulated cAMP signaling and downstream neuronal plasticity programs. In vitro and in vivo laboratory systems examine effects on synaptogenesis, spine-density markers and cognition-related pathways under controlled experimental conditions.
Primary Research Areas
-
PDE4D / cAMP signaling: Allosteric inhibition and pathway modulation in neuronal models.
-
Synaptogenesis & neuroplasticity: Structural and functional markers in cell-based and animal systems.
-
Cognition-related endpoints: Learning/memory readouts and transcriptional programs in research models.
-
Inflammatory & stress pathways: Cytokine and resilience markers linked to cAMP/PKA signaling.
